Imugene Limited (F:ILA) — Market Cap & Net Worth
Market Cap & Net Worth: Imugene Limited (ILA)
Imugene Limited (F:ILA) has a market capitalization of $30.88 Million (€26.41 Million) as of April 21, 2026. Listed on the F stock exchange, this Germany-based company holds position #26351 globally and #3731 in its home market, demonstrating a 4.46% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Imugene Limited's stock price €0.08 by its total outstanding shares 322081322 (322.08 Million).
Imugene Limited Market Cap History: 2026 to 2026
Imugene Limited's market capitalization history from 2026 to 2026. Data shows growth from $30.88 Million to $30.88 Million (0.00% CAGR).
Imugene Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Imugene Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ILA by Market Capitalization
Companies near Imugene Limited in the global market cap rankings as of April 21, 2026.
Key companies related to Imugene Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $111.94 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #298 globally with a market cap of $77.99 Billion USD.
- UCB SA (BR:UCB): Ranked #455 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx SE (SA:A1RG34): Ranked #456 globally with a market cap of $51.73 Billion USD ( R$263.66 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $111.94 Billion | $441.20 |
| #298 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $77.99 Billion | $750.57 |
| #455 | UCB SA | BR:UCB | $51.74 Billion | €263.90 |
| #456 | argenx SE | SA:A1RG34 | $51.73 Billion | R$169.59 |
Imugene Limited Historical Marketcap From 2026 to 2026
Between 2026 and today, Imugene Limited's market cap moved from $30.88 Million to $ 30.88 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €30.88 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 20th, 2026 the market cap of Imugene Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $30.88 Million USD |
| MoneyControl | $30.88 Million USD |
| MarketWatch | $30.88 Million USD |
| marketcap.company | $30.88 Million USD |
| Reuters | $30.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Imugene Limited
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more